KEYNOTE-671 — Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy in Resectable NSCLC

Phase 3 · 2023 · Non-Small Cell Lung Cancer

Design

Randomized neoadjuvant chemotherapy plus pembrolizumab or placebo, surgery, then adjuvant pembrolizumab or placebo.

Population

Resectable stage II-IIIB NSCLC, no EGFR/ALK alterations.

Primary Endpoint

event-free survival (EFS) and overall survival (OS)

Key Result

EFS 47.2 vs 18.3 mo (HR 0.59); OS not reached vs 52.4 mo (HR 0.72, P=0.0052); pCR 18.1% vs 4.0%.

Guideline Impact

NCCN-recommended perioperative pembrolizumab for resectable stage II-IIIB NSCLC